AMAG Pharma (AMAG) Posts Q1 Loss of $1.06, Sales Miss Views

AMAG Pharma (NASDAQ: AMAG) reported Q1 EPS of ($1.06), which may not compare to the analyst estimate of $1.64. Revenue for the quarter came in at $140.8 million versus the consensus estimate of $152.35 million.

GUIDANCE:

AMAG Pharma sees FY2017 revenue of $625-685 million, versus the consensus of $644.23 million.

For earnings history and earnings-related data on AMAG Pharma (AMAG) click here.

You May Also Be Interested In

• Tesla plans 'flying' Roadster stunt at SpaceX Texas site as early as August
• Outlook Therapeutics (OTLK) Misses Q3 EPS by 9c
• Star Equity Holdings (STRR) Misses Q2 EPS by 8c